AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24577019 — intervention group
Group type: COMPARATOR
Intervention: Episodes of severe bradycardia (heart rate ≤ 50 beats/min)
Number of subjects: 33
Study 24577019 — intervention group
Group type: COMPARATOR
Intervention: Episodes of hypotension (systolic BP ≤ 90 mm Hg)
Number of subjects: 33
Study 21796409 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 108
Study 21796409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 108
Study 21796409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (SET)
Number of subjects: 108
Study 21796409 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 108
Study 20939245 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with bone turnover markers
Number of subjects: 781
Study 20939245 — intervention group
Group type: COMPARATOR
Intervention: No biofeedback
Number of subjects: 781
Study 18845330 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 54
Study 18845330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16553198 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle catheter jejunostomy (NCJ)
Number of subjects: 37
Study 16553198 — intervention group
Group type: COMPARATOR
Intervention: Standard 'Witzel' tube jejunostomy (STJ)
Number of subjects: 37
Study 16553198 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral nutrition (EPEN) via jejunostomy
Number of subjects: 37
Study 16553198 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunostomy and EPEN on first operation
Number of subjects: 37
Study 16553198 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunostomy done at reoperation
Number of subjects: 37
Study 11954942 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril treatment
Number of subjects: 100
Study 11954942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 10362386 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (40 mg, two patches) administered 12 hours before exercise
Number of subjects: 25
Study 10362386 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches administered 12 hours before exercise
Number of subjects: 25
Study 7677554 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-skills training (two courses: problem-defining skills and emotion-handling skills)
Number of subjects: 648
Study 7677554 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-skills training
Number of subjects: 648
Study 7677554 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 648
Study 2209320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 37
Study 2209320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6108588 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 11
Study 6108588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 11
Study 6108588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 11
Study 6108588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29876831 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 91
Study 29876831 — intervention group
Group type: COMPARATOR
Intervention: Social activity intervention
Number of subjects: 91
Study 29205807 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 179
Study 29205807 — intervention group
Group type: COMPARATOR
Intervention: Clinic review
Number of subjects: 179
Study 28531791 — intervention group
Group type: EXPERIMENTAL
Intervention: Brioche group (65 g brioche enriched in protein and energy, 12.8 g protein, 180 kcal)
Number of subjects: 68
Study 28531791 — intervention group
Group type: EXPERIMENTAL
Intervention: Brioche group
Number of subjects: 68
Study 28531791 — intervention group
Group type: COMPARATOR
Intervention: Supplement group (200-ml energy-dense liquid, 14 g protein, 200 kcal)
Number of subjects: 68
Study 28531791 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual breakfast only)
Number of subjects: 68
Study 24668358 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability program
Number of subjects: 22
Study 24668358 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented motor training program
Number of subjects: 22
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 20 mg bid
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 30 mg bid
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg once-daily
Number of subjects: 498
Study 22464973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: All JNJ-37822681 groups
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Number of subjects: 498
Study 22464973 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid vs Olanzapine
Number of subjects: 498
Study 20080287 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 22
Study 20080287 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg
Number of subjects: 22
Study 20080287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17628221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and caffeine
Number of subjects: 12
Study 17628221 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and placebo
Number of subjects: 12
Study 15902278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 0.75% (6 patients)
Number of subjects: 11
Study 15902278 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (5 patients)
Number of subjects: 11
Study 12809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index at T0
Number of subjects: 140
Study 12809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index at T2
Number of subjects: 140
Study 12809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed walking test at T2
Number of subjects: 140
Study 12809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size
Number of subjects: 140
Study 12809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalability coefficients
Number of subjects: 140
Study 10942231 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA followed by three courses of daunorubicin-AraC chemotherapy
Number of subjects: 101
Study 10942231 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 101
Study 10942231 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 101
Study 8826020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 24
Study 8826020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 24
Study 8826020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 24
Study 8826020 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 24
Study 8826020 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study 1603224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (9 g a day)
Number of subjects: 19
Study 1603224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6141858 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg orally
Number of subjects: 0
Study 6141858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31213044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (U) group
Number of subjects: 150
Study 31213044 — intervention group
Group type: COMPARATOR
Intervention: Palpation (P) group
Number of subjects: 150
Study 30103096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 30103096 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 26898748 — intervention group
Group type: COMPARATOR
Intervention: Intensive Behavior Therapy fee-for-service (FFS) model
Number of subjects: 1440
Study 26898748 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered medical home (PCMH) model
Number of subjects: 1440
Study 26898748 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized disease management (DM) model
Number of subjects: 1440
Study 23761378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-activity allele of MAOA uVNTR polymorphism in girls
Number of subjects: 1101
Study 23761378 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of negative familial stressors
Number of subjects: 1101
Study 23761378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress level in girls with high-activity allele
Number of subjects: 1101
Study 23761378 — intervention group
Group type: COMPARATOR
Intervention: Boys with MAOA uVNTR polymorphism
Number of subjects: 1101
Study 22962858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print reminder
Number of subjects: 1859
Study 22962858 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored print reminder
Number of subjects: 1859
Study 19679557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 2450
Study 18622251 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen (n = 12)
Number of subjects: 25
Study 18622251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril-based regimen (n = 13)
Number of subjects: 25
Study 15913920 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (up to 300 mg per day)
Number of subjects: 111
Study 15913920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 15913920 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 111
Study 12101597 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100
Study 12101597 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drugs (Control)
Number of subjects: 100
Study 9520056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone
Number of subjects: 20
Study 9520056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline and sodium hyaluronate)
Number of subjects: 20
Study 7977124 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated backscatter imaging in patients with nonrestrictive ventricular septal defect
Number of subjects: 16
Study 7977124 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic analysis of myocardial tissue in patients
Number of subjects: 16
Study 2574732 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 16
Study 2574732 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 16
Study 2574732 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 16
Study 2574732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1095122 — intervention group
Group type: COMPARATOR
Intervention: Nafoxidine (reference compound)
Number of subjects: 76
Study 1095122 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 76
Study 30516871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 85
Study 30516871 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 85
Study 29336881 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracted endodontic cavities (CECs)
Number of subjects: 30
Study 29336881 — intervention group
Group type: COMPARATOR
Intervention: Traditional endodontic cavities (TECs)
Number of subjects: 30
Study 26682780 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soft drink consumers
Number of subjects: 488
Study 26682780 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened soft drink consumers
Number of subjects: 488
Study 26682780 — intervention group
Group type: COMPARATOR
Intervention: Nonconsumers
Number of subjects: 488
Study 24643427 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS + Exercise (BFR resistance training on KE three times per week during ULLS)
Number of subjects: 16
Study 24643427 — intervention group
Group type: COMPARATOR
Intervention: ULLS (control group)
Number of subjects: 16
Study 24643427 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS + Exercise
Number of subjects: 16
Study 22846643 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose acupuncture (additional 4 needles at non‐acupoints bilaterally)
Number of subjects: 52
Study 22846643 — intervention group
Group type: COMPARATOR
Intervention: Low dose acupuncture (one needle at point Hegu bilaterally)
Number of subjects: 52
Study 22846643 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Number of subjects: 52
Study 22846643 — intervention group
Group type: COMPARATOR
Intervention: Low dose acupuncture
Number of subjects: 52
Study 19996308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study 18990229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 27
Study 18990229 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 15767357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied using recommended application techniques
Number of subjects: 30
Study 15767357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen reapplied after 3 hours
Number of subjects: 30
Study 15767357 — intervention group
Group type: COMPARATOR
Intervention: Control swabs (no sunscreen)
Number of subjects: 30
Study 12387962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 910
Study 12387962 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 910
Study 9698663 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy (group 1, n = 217)
Number of subjects: 444
Study 9698663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral polyoestradiol phosphate (PEP) 240 mg/month (group 2, n = 227)
Number of subjects: 444
Study 9698663 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cardiovascular complications between groups
Number of subjects: 444
Study 7616460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 30
Study 7616460 — intervention group
Group type: COMPARATOR
Intervention: Attention/placebo group (APG)
Number of subjects: 30
Study 2654335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 151
Study 2654335 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy
Number of subjects: 151
Study 2654335 — intervention group
Group type: EXPERIMENTAL
Intervention: Open discectomy after chemonucleolysis
Number of subjects: 151
Study 2654335 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of final results
Number of subjects: 151
Study 2654335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 151
Study 69058 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 11958
Study 7137990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine HCl 25 mg in saline (10 min exposure twice daily)
Number of subjects: 36
Study 7137990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rimantadine HCl 50 mg (every 6 h, three times daily)
Number of subjects: 36
Study 7137990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (both aerosol and oral routes)
Number of subjects: 36
Study 7137990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine and oral rimantadine
Number of subjects: 36
Study 31389599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 210
Study 31389599 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 210
Study 28299764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of furosemide (120 mg stat)
Number of subjects: 50
Study 28299764 — intervention group
Group type: COMPARATOR
Intervention: Infusion of furosemide (4 mg/minute)
Number of subjects: 50
Study 28299764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection and infusion of furosemide
Number of subjects: 50
Study 27219099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered before viewing images (encoding condition)
Number of subjects: 59
Study 27219099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered immediately after viewing images (consolidation condition)
Number of subjects: 59
Study 27219099 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered both before and after viewing images (control condition)
Number of subjects: 59
Study 27219099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) in encoding condition with greater alcohol-induced stimulation
Number of subjects: 59
Study 23723317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab retreatment at 1000 mg×1 (Arm A)
Number of subjects: 143
Study 23723317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab retreatment at 1000 mg×2 (Arm B)
Number of subjects: 143
Study 22371301 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 36
Study 22371301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19437182 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a pedometer
Number of subjects: 102
Study 19437182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 17689948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (C), n=22, 80% of pre-training peak work rate
Number of subjects: 71
Study 17689948 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (I), n=17, 30 min cycling (2 min at 90% peak work rate, 1 min at 50% peak work rate, bracketed by 7.5 min at 50% peak work rate)
Number of subjects: 71
Study 17689948 — intervention group
Group type: COMPARATOR
Intervention: Self-paced training (S), n=32, instructed to cycle, climb stairs and walk at home
Number of subjects: 71
Study 17689948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (C) and Interval training (I)
Number of subjects: 71
Study 17689948 — intervention group
Group type: COMPARATOR
Intervention: All groups (C, I, S)
Number of subjects: 71
Study 15650985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.5 mg/kg/h
Number of subjects: 20
Study 15650985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 1.0 mg/kg/h
Number of subjects: 20
Study 15650985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.5 mg/kg/h and 1.0 mg/kg/h
Number of subjects: 20
Study 11205921 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 activity in T cells
Number of subjects: 22
Study 11205921 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell apoptosis
Number of subjects: 22
Study 11205921 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-zeta molecule expression
Number of subjects: 22
Study 11205921 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma production
Number of subjects: 22
Study 11205921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha production
Number of subjects: 22
Study 9698139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth count tertiles (extreme groups)
Number of subjects: 1365
Study 9698139 — intervention group
Group type: COMPARATOR
Intervention: WHO criteria for BMD
Number of subjects: 1365
Study 7992446 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 kJ/day diet with combined aerobic and anaerobic exercise
Number of subjects: 121
Study 7992446 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 kJ/day diet
Number of subjects: 121
Study 7992446 — intervention group
Group type: COMPARATOR
Intervention: controls (no intervention)
Number of subjects: 121
Study 2648188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g/kg protein diet
Number of subjects: 5
Study 2648188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg diet with protein evenly distributed between meals
Number of subjects: 5
Study 2648188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg diet with protein restricted to the evening meal
Number of subjects: 5
Study 10697473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate
Number of subjects: 0
Study 10697473 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 0
Study 31898804 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based navigation
Number of subjects: 12
Study 31898804 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 12
Study 30794334 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide with probiotic supplements (BP)
Number of subjects: 152
Study 30794334 — intervention group
Group type: COMPARATOR
Intervention: Budesonide with placebo (B)
Number of subjects: 152
Study 29029260 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV postfusion F protein vaccine (120 µg) with glucopyranosyl lipid adjuvant (5 µg)
Number of subjects: 1894
Study 29029260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1894
Study 29029260 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV postfusion F protein vaccine
Number of subjects: 1894
Study 25599284 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg plus optimized background regimen (OBR)
Number of subjects: 81
Study 23568514 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized hypnotherapeutic‐behavioral treatment (n = 20)
Number of subjects: 38
Study 23568514 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (n = 18)
Number of subjects: 38
Study 23568514 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (both groups)
Number of subjects: 38